Compare D R Horton Inc (DHI) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Incyte Corporation — how do they compare? D R Horton Inc trades at $151.5 (market cap $42.53B), while Incyte Corporation trades at $114.99 (market cap $22.95B). The key difference: D R Horton Inc is the larger of the two by market cap, and D R Horton Inc pays a 1.2% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| DHI | INCY | |
|---|---|---|
Market Cap | $42.53B | $22.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $118.52 |
52-Week Low | $129.82 | $67.38 |
Enterprise Value | $47.25B | $18.97B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $148.85, down 1.8% over 24 hours, with a bearish technical signal from moving averages but oversold RSI levels. The company reported mixed quarterly earnings, beating estimates in Q4 2025 and Q1 2026 but missing in Q3 2025, with revenue declining to $34.25 billion in 2025. Analyst consensus is split between Buy and Hold ratings, with a $164.71 price target suggesting potential upside. Recent news highlights housing market headwinds from rising mortgage rates but also potential support from new legislation.
DHI presents a cautious opportunity with attractive valuation multiples (P/E 13.98, P/S 1.32) and a stable dividend, but faces risks from housing affordability pressures and volatile cash flows. Investors should weigh the company's scale and market position against macroeconomic challenges in the homebuilding sector.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
